Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Hamai, Kosuke ^a   Iwamoto, Hiroshi ^a   Ishikawa, Nobuhisa ^b   Horimasu, Yasushi ^a   Masuda, Takeshi ^a   Miyamoto, Shintaro ^a   Nakashima, Taku ^a   Ohshimo, Shinichiro ^a   Fujitaka, Kazunori ^a   Hamada, Hironobu ^a   Hattori, Noboru ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CC CHEMOKINE LIGAND 18; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; KREBS VON DEN LUNGEN 6 PROTEIN; MATRILYSIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; BETA CHEMOKINE; CCL18 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; MUCIN 1;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE MARKER; FEMALE; FIBROSING ALVEOLITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; SURVIVAL PREDICTION; SURVIVAL RATE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROGNOSIS;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHEMOKINES, CC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; MUCIN-1; PNEUMONIA, BACTERIAL; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; SURVIVAL RATE;

EID: 84973176769     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/4759040     Document Type: Article

References (32)

1. G. Raghu, H. R. Collard, J. J. Egan et al., "An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management," American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788-824, 2011.
2. D. A. Schwartz, R. A. Helmers, J. R. Galvin et al., "Determinants of survival in idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 2, part 1, pp. 450-454, 1994.
3. T. E. King Jr., J. A. Tooze, M. I. Schwarz, K. R. Brown, and R. M. Cherniack, "Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 7, pp. 1171-1181, 2001.
4. N. Kohno, S. Kyoizumi, Y. Awaya, H. Fukuhara, M. Yamakido, and M. Akiyama, "New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6," Chest, vol. 96, no. 1, pp. 68-73, 1989.
5. N. Kohno, Y. Awaya, T. Oyama et al., "KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease," American Review of Respiratory Disease, vol. 148, no. 3, pp. 637-642, 1993.
6. Y. Kuroki, H. Takahashi, H. Chiba, and T. Akino, "Surfactant proteins A and D: disease markers," Biochimica et Biophysica Acta, vol. 1408, no. 2-3, pp. 334-345, 1998.
7. A. Yokoyama, K. Kondo, M. Nakajima et al., "Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis," Respirology, vol. 11, no. 2, pp. 164-168, 2006.
8. H. Takahashi, M. Shiratori, A. Kanai, H. Chiba, Y. Kuroki, and S. Abe, "Monitoringmarkers of disease activity for interstitial lung diseases with serum surfactant proteins A and D," Respirology, vol. 11, no. 1, pp. S51-S54, 2006.
9. H. Ohnishi, A. Yokoyama, K. Kondo et al., "Comparative study of KL-6, surfactant protein-A, surfactant protein-D, andmonocyte chemoattractant protein-1as serum markers for interstitial lung diseases," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 3, pp. 378-381, 2002.
10. S. Fujishima, T. Shiomi, S. Yamashita et al., "Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis," Archives of Pathology and Laboratory Medicine, vol. 134, no. 8, pp. 1136-1142, 2010.
11. I. O. Rosas, T. J. Richards, K. Konishi et al., "MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis," PLoS Medicine, vol. 5, no. 4, article e93, 2008.
12. J.W. Song, K.H. Do, S. J. Jang, T. V. Colby, S. Han, and D. S. Kim, "Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis," Chest, vol. 143, no. 5, pp. 1422-1429, 2013.
13. A. Prasse, C. Probst, E. Bargagli et al., "Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 8, pp. 717-723, 2009.
14. M. R. Miller, R. Crapo, J. Hankinson et al., "General considerations for lung function testing," European Respiratory Journal, vol. 26, no. 1, pp. 153-161, 2005.
15. J. J. Deeks, "Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests," British Medical Journal, vol. 323, no. 7305, pp. 157-162, 2001.
16. S. Landau and B. S. Everitt, A Handbook of Statistical Analysis Using SPSS, Chapman & Hall/CRC, BocaRaton, Fla, USA, 2004.
17. S. Ohshimo, N. Ishikawa, Y. Horimasu et al., "Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis," Respiratory Medicine, vol. 108, no. 7, pp. 1031-1039, 2014.
18. L. Kang, W. Chen, N. A. Petrick, and B. D. Gallas, "Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach," Statistics in Medicine, vol. 34, no. 4, pp. 685-703, 2015.
19. R. M. du Bois, D. Weycker, C. Albera et al., "Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 4, pp. 459-466, 2011.
20. H. Satoh, K. Kurishima, H. Ishikawa, and M. Ohtsuka, "Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases," Journal of Internal Medicine, vol. 260, no. 5, pp. 429-434, 2006.
21. T. J. Richards, N. Kaminski, F. Baribaud et al., "Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 1, pp. 67-76, 2012.
22. Y. Hirasawa, N. Kohno, A. Yokoyama, Y. Inoue, M. Abe, and K. Hiwada, "KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts," American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 4, pp. 501-507, 1997.
23. S. Ohshimo, A. Yokoyama, N. Hattori, N. Ishikawa, Y. Hirasawa, and N. Kohno, "KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts," Biochemical and Biophysical Research Communications, vol. 338, no. 4, pp. 1845-1852, 2005.
24. A. Pardo, M. Selman, and N. Kaminski, "Approaching the degradome in idiopathic pulmonary fibrosis," International Journal of Biochemistry and Cell Biology, vol. 40, no. 6-7, pp. 1141-1155, 2008.
25. F. Zuo, N. Kaminski, E. Eugui et al., "Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6292-6297, 2002.
26. Y. Yasuda, K. Kasahara, F. Mizuno, K. Nishi, K. Mikasa, and E. Kita, "Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model," Antimicrobial Agents and Chemotherapy, vol. 51, no. 5, pp. 1741-1752, 2007.
27. S. P. Atamas, I. G. Luzina, J. Choi et al., "Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts," American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 6, pp. 743-749, 2003.
28. K. Pochetuhen, I. G. Luzina, V. Lockatell, J. Choi, N. W. Todd, and S. P. Atamas, "Complex regulation of pulmonary inflammation and fibrosis by CCL18," The American Journal of Pathology, vol. 171, no. 2, pp. 428-437, 2007.
29. E. Schutyser, S. Struyf, A. Wuyts et al., "Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis," European Journal of Immunology, vol. 31, no. 12, pp. 3755-3762, 2001.
30. G. Ferrara, B. Bleck, L. Richeldi et al., "Mycobacterium tuberculosis induces CCL18 expression in human macrophages," Scandinavian Journal of Immunology, vol. 68, no. 6, pp. 668-674, 2008.
31. H. Ishii, H. Mukae, J. Kadota et al., "High serumconcentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia," Thorax, vol. 58, no. 1, pp. 52-57, 2003.
32. M. Cai, F. Bonella, X. He et al., "CCL18 in serum, BAL fluid and alveolarmacrophage culture supernatant in interstitial lung diseases," Respiratory Medicine, vol. 107, no. 9, pp. 1444-1452, 2013.